News
09-29-2014, 10:51 PM
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
More... (http://www.news-medical.net/news/20140930/Abbvie-announces-multiple-study-results-of-veliparib-investigational-compound-in-NSCLC-patients.aspx)
More... (http://www.news-medical.net/news/20140930/Abbvie-announces-multiple-study-results-of-veliparib-investigational-compound-in-NSCLC-patients.aspx)